DBVT Overview

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is46.40 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dbv Technologies SA revenue for the last quarter amounts to 645.00K USD, increased 26.22

Dbv Technologies SA. EPS for the last quarter amounts to -0.24 USD, increased 4.35

Dbv Technologies SA (DBVT) has 108 emplpoyees as of April 22 2026.

Today DBVT has the market capitalization of 1.24B USD.